Oral Session 1-5B AML: Novel agents

[OS1-5B-3] Phase 1 of venetoclax (VEN) combined with azacitidine in Japanese (JPN) patients (Pts) with AML

Ilseung Choi¹, Takahiro Yamauchi², Shuichi Taniguchi³, Noriko Fukuhara⁴, Jalaja Potluri⁵, Paulo Maciag⁵, Hideyuki Honda⁶, Suresh K. Agarwal⁵, Kensuke Usuki⁷ (1.Department of Hematology, National Hospital Organization, Kyushu Cancer Center, Fukuoka-Shi, Japan, 2.Department of Hematology and Oncology, University of Fukui Hospital, Yoshida-gun, Japan, 3.Department of Hematology, Toranomon Hospital, Minato-ku, Japan, 4.Department of Hematology and Rheumatology, Tohoku University Hospital, Seiryo-cho, Japan, 5.AbbVie Inc., North Chicago, United States of America, 6.AbbVie GK, Minato-ku, Japan, 7.Department of Hematology, NTT Medical Center Tokyo, Shinagawa-ku, Japan)